心血管

订阅

MedSci主页 / 所有栏目 / 心血管

PhaseBio宣布开展PB1046治疗肺动脉高压的IIb期临床试验

2018-11-28 MedSci MedSci原创

PB1046PhaseBio肺动脉高压
关注

PhaseBio是一家临床阶段的生物制药公司，专注于孤儿疾病新疗法的开发和商业化，专注于心肺疾病，近日宣布，PB1046治疗肺动脉高压（PAH）的的IIb期临床试验将由华盛顿大学医学院（WUSM）医学博士Murali Chakinala和Barnes-Jewish医院肺动脉高压护理中心开展。

PhaseBio是一家临床阶段的生物制药公司，专注于孤儿疾病新疗法的开发和商业化，专注于心肺疾病，近日宣布，PB1046治疗肺动脉高压（PAH）的的IIb期临床试验将由华盛顿大学医学院（WUSM）医学博士Murali Chakinala和Barnes-Jewish医院肺动脉高压护理中心开展。PB1046是人类血管活性肠肽（VIP）的缓释类似物，与PhaseBio专有的ELP半衰期延伸技术相融合。随机、双盲、平行组IIb期试验将评估在约60名PAH患者中每周一次皮下注射PB1046的安全性、耐受性和有效性。该试验将通过六分钟步行试验，评估PB1046对肺血流动力学和运动耐量的影响。PhaseBio首席医疗官John Lee博士说：“利用我们的ELP技术，显著延长了PB1046的血浆半衰期”。

肺动脉高压是肺部动脉（肺动脉）血压力异常增高的一种疾病。患者表现劳力性气短和精力缺乏，一些患者劳力时感觉头晕眼花或疲劳，疾病如何发生并不十分清楚。随着病程的推移，一些肺动脉会硬化，甚至会被完全堵塞。


原始出处：

http://www.firstwordpharma.com/node/1607286#axzz5Y7c6A8OV

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2019-06-25 bioon3

    #Ib期#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2019-05-31 lfyang

    #PB1046#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2019-04-17 jklm09

    #动脉高压#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2019-06-26 chentianping

    #Phase#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2019-09-30 sunylz

    #Bio#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2019-11-14 智慧医人

    #EBI#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2018-11-29 明天jing

    肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1940328, encodeId=ff7f19403289f, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Jun 25 13:35:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755538, encodeId=d1da1e555387c, content=<a href='/topic/show?id=c0991381242' target=_blank style='color:#2F92EE;'>#PB1046#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13812, encryptionId=c0991381242, topicName=PB1046)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c836942824, createdName=lfyang, createdTime=Fri May 31 05:35:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925264, encodeId=271e192526483, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 17 06:35:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788713, encodeId=2fb21e8871320, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 26 15:35:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918420, encodeId=1cfd1918420d2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 30 03:35:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997104, encodeId=07be199e104e1, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 14 09:35:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050827, encodeId=1266105082e50, content=肺动脉高压表面是罕见病，事实上临床上并不少见，治疗药物虽然有一些，但是整体仍然不理解，可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Nov 29 02:35:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353927, encodeId=473b35392e7c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Nov 29 00:18:27 CST 2018, time=2018-11-29, status=1, ipAttribution=)]
    2018-11-29 smartxiuxiu

    好

    0